Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
2 hedge funds and large institutions have $28.1K invested in Dermata Therapeutics Warrant in 2025 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
145% more capital inflows, than outflows
Capital inflows: $54 | Capital outflows: $22
0.06% more ownership
Funds ownership: 1.25% → 1.32% (+0.06%)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$54 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$22 |
DRMAW Hedge Fund Activity: Q4 2025 in Review
2 of the 8,288 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q4 2025, worth a combined $28.1K — down 54% from $60.5K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of DRMAW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, adding an estimated $54. The largest seller was UBS Group, exiting entirely with an estimated $22 sold.
- 2 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q4 2025, down from 3 in Q3 2025.
- Funds reported $28.1K of Dermata Therapeutics Warrant stock for Q4 2025, down 54% quarter-over-quarter.
- 0 funds opened new Dermata Therapeutics Warrant positions in Q4 2025 and 1 closed out, a net change of -1 holder.
- The largest Dermata Therapeutics Warrant buyer in Q4 2025 was Susquehanna International Group, an estimated $54 added.
- The largest Dermata Therapeutics Warrant seller in Q4 2025 was UBS Group, an estimated $22 sold.
Based on aggregated 13F filings for Q4 2025.